Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 14.34% | Reduce −38.4% | 987,153 | $76.29 | $75M | −616,312 | −$35M |
| BMRN - Biomarin Pharmaceutical | 13.34% | Reduce −7.1% | 991,207 | $70.69 | $70M | −76,059 | −$83K |
| FOLD - Amicus | 11.41% | Reduce −4.1% | 7,345,002 | $8.16 | $60M | −317,477 | −$12M |
| ACAD - Acadia Pharmaceuticals | 8.43% | Reduce −3.1% | 2,663,925 | $16.61 | $44M | −84,674 | −$6M |
| UTHR - United Therapeutics | 6.18% | Reduce −32.4% | 105,228 | $308.27 | $32M | −50,486 | −$23M |
| BIIB - Biogen | 5.34% | Add +7.8% | 204,923 | $136.84 | $28M | +14,775 | −$1M |
| ALNY - Alnylam Pharmaceuticals | 4.29% | Reduce −40.7% | 83,488 | $270.02 | $23M | −57,193 | −$11M |
| PTC - Ptc Therapeutics | 3.92% | Add +4.6% | 404,196 | $50.96 | $21M | +17,783 | +$3M |
| PRTA - Prothena | 3.91% | Reduce −4.5% | 1,659,734 | $12.37 | $21M | −78,230 | −$4M |
| ANAB - Anaptysbio | 3.61% | Add +20.9% | 1,020,713 | $18.59 | $19M | +176,742 | +$8M |
| NVCR - Novocure | 3.40% | Add +23.1% | 1,002,061 | $17.82 | $18M | +187,870 | −$6M |
| Sarepta Therapeutics | 2.56% | Hold | 210,258 | $63.82 | $13M | — | — |
| EHTH - Ehealth | 2.14% | Reduce −10.3% | 1,684,336 | $6.68 | $11M | −193,791 | −$6M |
| IOVA - Iovance Biotherapeutics | 2.04% | Add +5.6% | 3,211,314 | $3.33 | $11M | +169,629 | −$12M |
| Staar Surgical | 1.76% | Add +4.8% | 525,017 | $17.63 | $9M | +24,242 | −$3M |
| AGIO - Agios Pharmaceuticals | 1.54% | New | 276,578 | $29.30 | $8M | +276,578 | +$8M |
| ALKS - Alkermes | 1.39% | Reduce −23.4% | 221,513 | $33.02 | $7M | −67,795 | −$1M |
| Gossamer Bio | 1.31% | Reduce 0.0% | 6,276,893 | $1.10 | $7M | −200 | +$1M |
| ALGN - Align Technology | 1.14% | Hold | 37,772 | $158.86 | $6M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.04% | Add +9.7% | 444,367 | $12.29 | $5M | +39,174 | +$102K |
| Acelyrin | 0.84% | Hold | 1,792,895 | $2.47 | $4M | — | — |
| DYN - Dyne Therapeutics | 0.66% | New | 333,391 | $10.46 | $3M | +333,391 | +$3M |
| MIRM - Mirum Pharmaceuticals | 0.56% | Hold | 64,700 | $45.05 | $3M | — | — |
| EW - Edwards Lifesciences | 0.54% | Hold | 39,473 | $72.48 | $3M | — | — |
| Verve Therapeutics | 0.50% | Hold | 575,817 | $4.57 | $3M | — | — |
| BNTX - Biontech Se- | 0.44% | Hold | 25,206 | $91.06 | $2M | — | — |
| BCYC — | 0.40% | Hold | 248,934 | $8.49 | $2M | — | — |
| TVTX - Travere Therapeutics | 0.38% | Hold | 110,719 | $17.92 | $2M | — | — |
| TSHA - Taysha Gene Therapies | 0.38% | Add +75.0% | 1,419,468 | $1.39 | $2M | +608,200 | +$570K |
| NBIX - Neurocrine Biosciences | 0.28% | New | 13,334 | $110.60 | $1M | +13,334 | +$1M |
| NUVB - Nuvation Bio · CL A | 0.26% | Hold | 772,652 | $1.76 | $1M | — | — |
| ALDX - Aldeyra Therapeutics | 0.25% | Hold | 225,465 | $5.75 | $1M | — | — |
| Karyopharm Therapeutics | 0.23% | Reduce −93.4% | 324,032 | $3.74 | $1M | −4,582,969 | −$2M |
| ACRS - Aclaris Therapeutics | 0.23% | Add +36.2% | 776,028 | $1.53 | $1M | +206,196 | −$226K |
| HUM - Humana | 0.20% | Hold | 3,985 | $264.60 | $1M | — | — |
| PYXS - Pyxis Oncology | 0.19% | Hold | 1,037,421 | $0.9799 | $1M | — | — |
| STOK - Stoke Therapeutics | 0.16% | Hold | 125,861 | $6.65 | $837K | — | — |
| Vyne Therapeutics Pipe | 0.13% | Hold | 445,434 | $1.58 | $704K | — | — |
| ABEO - Abeona Therapeutics | 0.10% | Hold | 108,865 | $4.76 | $518K | — | — |
| URGN - Urogen Pharma | 0.05% | Hold | 24,500 | $11.06 | $271K | — | — |
| Instil Bio | 0.04% | Hold | 11,165 | $17.36 | $194K | — | — |
| Akari Therapeutics - | 0.03% | Hold | 146,024 | $1.24 | $181K | — | — |
| RLMD - Relmada Therapeutics | 0.03% | Hold | 495,146 | $0.2700 | $134K | — | — |
| Generation Bio | 0.01% | Hold | 150,475 | $0.4050 | $61K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Nevro | 0.43% | Exit | 0 | $3.72 | $3M | −750,371 | −$3M |
| Jasper Therapeutics | 0.10% | Exit | 0 | $21.37 | $655K | −30,651 | −$655K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2